Patents by Inventor Karen Heyninck

Karen Heyninck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA
    Publication number: 20240301049
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 28, 2023
    Publication date: September 12, 2024
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brige, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-?
    Patent number: 11897951
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: February 13, 2024
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF-a
    Publication number: 20220356241
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: November 10, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND OX40L
    Publication number: 20210188986
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an autoimmune or inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to TNF? and at least two ISVDs binds to OX4OL. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Peter Florian, Karen Heyninck, Thomas Kreutzberg, Thomas Leeuw, Eric Lorent, Oezen Sercan Alp, Gertrud Sibenhorn
  • Inhibitors of MALT1 proteolytic activity and uses thereof
    Patent number: 8309523
    Abstract: The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: November 13, 2012
    Assignees: VIB VZW, Universiteit Gent, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Rudi Beyaert, Peter Marynen, Thijs Baens, Karen Heyninck
  • INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF
    Publication number: 20110021548
    Abstract: The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity.
    Type: Application
    Filed: November 20, 2008
    Publication date: January 27, 2011
    Inventors: Rudi Beyaert, Peter Marynen, Thijs Baens, Karen Heyninck
  • Inhibitors of NF-kappaB activation
    Patent number: 7414026
    Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-?B) activating pathway useful in the treatment of NF-?B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I?B.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: August 19, 2008
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
  • Novel inhibitors of NF-kappaB activation
    Publication number: 20040092430
    Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-&kgr;B) activating pathway useful in the treatment of NF-&kgr;B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I&kgr;B.
    Type: Application
    Filed: October 8, 2003
    Publication date: May 13, 2004
    Inventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
  • Inhibitors of NF-&kgr;B Activation
    Patent number: 6673897
    Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-&kgr;B) activating pathway useful in the treatment of NF-&kgr;B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I&kgr;B.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: January 6, 2004
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Rudi Beyaert, Karen Heyninck, Walter Fiers